Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research

Simple item page
dc.contributor.authorGuastella, AJen_AU
dc.contributor.authorHickie, IBen_AU
dc.contributor.authorMcGuinness, MMen_AU
dc.contributor.authorOtis, Men_AU
dc.contributor.authorWoods, EAen_AU
dc.contributor.authorDisinger, HMen_AU
dc.contributor.authorChan, Hen_AU
dc.contributor.authorChen, TFen_AU
dc.contributor.authorBanati, RBen_AU
dc.date.accessioned2014-10-06T23:57:20Zen_AU
dc.date.available2014-10-06T23:57:20Zen_AU
dc.date.issued2013-05-01en_AU
dc.date.statistics2014-10-07en_AU
dc.description.abstractA series of studies have reported on the salubrious effects of oxytocin nasal spray on social cognition and behavior in humans, across physiology (e.g., eye gaze, heart rate variability), social cognition (e.g., attention, memory, and appraisal), and behavior (e.g., trust, generosity). Findings suggest the potential of oxytocin nasal spray as a treatment for various psychopathologies, including autism and schizophrenia. There are, however, increasing reports of variability of response to oxytocin nasal spray between experiments and individuals. In this review, we provide a summary of factors that influence transmucosat nasal drug delivery, deposition, and their impact on bioavailability. These include variations in anatomy and resultant airflow dynamic, vascularisation, status of blood vessels, mode of spray application, gallenic formulation (including presence of uptake enhancers, control release formulation), and amount and method of administration. These key variables are generally poorly described and controlled in scientific reports, in spite of their potential to alter the course of treatment outcome studies. Based on this review, it should be of no surprise that differences emerge across individuals and experiments when nasal drug delivery methods are employed. We present recommendations for researchers to use when developing and administering the spray, and guidelines for reporting on peptide nasal spray studies in humans. We hope that these recommendations assist in establishing a scientific standard that can improve the rigor and subsequent reliability of reported effects of oxytocin nasal spray in humans. © 2013, Elsevier Ltd.en_AU
dc.identifier.citationGuastella, A. J., Hickie, I. B., McGuinness, M. M., Otis, M., Woods, E. A., Disinger, H. M., Chan, H., Chen, T. F., & Banati, R. B. (2013). Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology, 38(5), 612-625. doi:10.1016/j.psyneuen.2012.11.019en_AU
dc.identifier.govdoc5706en_AU
dc.identifier.issn0306-4530en_AU
dc.identifier.issue5en_AU
dc.identifier.journaltitlePsychoneuroendocrinologyen_AU
dc.identifier.pagination612-625en_AU
dc.identifier.urihttp://dx.doi.org/10.1016/j.psyneuen.2012.11.019en_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/5896en_AU
dc.identifier.volume38en_AU
dc.language.isoenen_AU
dc.publisherPergamon-Elsevier Science Ltden_AU
dc.subjectHormonesen_AU
dc.subjectPeptide hormonesen_AU
dc.subjectAbsorptionen_AU
dc.subjectPeptidesen_AU
dc.subjectDrugsen_AU
dc.subjectBrainen_AU
dc.titleRecommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human researchen_AU
dc.typeJournal Articleen_AU
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles